Cold chain in 2021: COVID-19’s continued influence
Dave Williams explores why the cold chain requirements for COVID-19 vaccines may have a lasting impact on the pharmaceutical supply chain.
List view / Grid view
Dave Williams explores why the cold chain requirements for COVID-19 vaccines may have a lasting impact on the pharmaceutical supply chain.
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
Richard Daniell explains why Europe needs a strong pharmaceutical manufacturing base and supply chain to ensure a resilient network.
Amgen has set out the company's seven-year environmental sustainability plan to achieve carbon neutrality by 2027.
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
According to the alliance, 70 poor countries will only be able to vaccinate one in 10 people against COVID-19 next year after rich countries bought up most prophylactics.
The EMA and HMA have published their joint strategy for the next five years, detailing how the regulatory network can continue the supply of safe and effective medicines.
Pfizer spokesperson reveals supply chain challenges and late clinical trial results contributed to its COVID-19 vaccine production target for 2020 being halved.
A group of hackers has sent phishing emails to various people involved in COVID-19 vaccine cold chain distribution to gain insight, IBM has revealed.
The UK's MHRA has given temporary emergency authorisation to Pfizer and BioNTech's COVID-19 vaccine, making it the first in the world to receive approval.
The pharmaceutical cold chain includes numerous participants – David Lewandowski discusses why this must be scalable to ensure efficient delivery of a COVID-19 vaccine.
UK Prime Minister Boris Johnson has announced a £20 million investment fund for medicine manufacturing and supply chains in the UK.
The strategy outlines actions to strengthen EU supply chains, encourage innovation and ensure medicines are affordable and sustainable.
PhRMA and other organisations have challenged action by the HHS and FDA that permits the importation of drugs from Canada without drug manufacturers’ oversight.
In this Q&A, Nick Pike, Chief Revenue Officer at Vizibl, outlines with EPR’s Hannah Balfour the benefits of Software as a Service (SaaS) for pharmaceutical companies and describes how its adoption can enable companies to achieve many goals faster; from collaborating on bringing new products to market to reaching their…